We are gearing up for the WuXi AppTec BOLD program: Innovation That Matters. On July 27-28, our Founder and CEO, Dr Zou Bin, will share his views and knowledge on the development of Antibody Drug Conjugates for cancer treatment and how Axcynsis Therapeutics aims to address challenges in the field. This digital event focusses on the fields of cancer, CNS, and rare diseases. Join us and other biotech companies in discovering innovative ways to create a lasting impact on the healthcare of tomorrow. Register here.


About Axcynsis Therapeutics Pte. Ltd.
Axcynsis Therapeutics Pte. Ltd. is a platform-based biotechnology company focusing on the development of Antibody Drug Conjugates (ADCs) to revolutionise cancer treatments. The Singapore biotech start-up leverages on proprietary technologies in its development of a robust pipeline of ADC candidates to address unmet medical needs for cancer treatment.

For all media queries, please contact: